Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Humacyte ( (HUMA) ) has provided an update.
On March 19, 2026, Humacyte suspended and terminated its at-the-market equity prospectus for up to $60 million in common stock sales with TD Securities, while leaving the underlying sales agreement in place and releasing a new investor presentation for use in outreach activities. The company also provided preliminary 2025 figures, indicating about $50.9 million in cash and $2.0 million in revenue with 61 Symvess units sold, underscoring early but modest commercial traction for its flagship vascular graft.
Operationally, Humacyte detailed a March 4, 2026 minimum purchase commitment of roughly $1.48 million for Symvess in Saudi Arabia to support surgeon education and hospital evaluations, alongside exclusive negotiations through July 2, 2026 on a potential joint venture and licensing deal. On March 16, 2026, the company filed a Marketing Authorization Application in Israel for Symvess in vascular trauma and is exploring hospital-level access pathways, steps that signal an effort to broaden international adoption while updating investors on evolving risk disclosures.
The most recent analyst rating on (HUMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.
Spark’s Take on HUMA Stock
According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.
The score is held down primarily by weak financial performance (large losses, heavy cash burn, and negative equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a more constructive earnings call with improving commercial traction and reduced net loss, plus recent financing/loan facilities that extend runway, but valuation remains difficult due to negative earnings.
To see Spark’s full report on HUMA stock, click here.
More about Humacyte
Humacyte, Inc. operates in regenerative medicine, developing bioengineered acellular tissue engineered vessels and other universally implantable human tissues and organs. Its lead product, Symvess, an FDA-approved acellular tissue engineered vessel for extremity vascular trauma, targets large markets including trauma, dialysis access, peripheral artery disease, diabetes and coronary bypass, supported by commercial-scale manufacturing capacity of up to 40,000 vessels annually.
Average Trading Volume: 5,189,256
Technical Sentiment Signal: Sell
Current Market Cap: $204.6M
For an in-depth examination of HUMA stock, go to TipRanks’ Overview page.